Cargando…

Tofogliflozin decreases body fat mass and improves peripheral insulin resistance

The impact of tofogliflozin, a sodium‐glucose co‐transporter‐2 inhibitor, on peripheral glucose uptake in patients with type 2 diabetes mellitus (T2DM) was investigated using the hyperinsulinaemic‐euglycaemic clamp method in a single‐arm, open‐label study. The following variables were compared betwe...

Descripción completa

Detalles Bibliográficos
Autores principales:	Matsuba, Ren, Matsuba, Ikuro, Shimokawa, Mototsugu, Nagai, Yoshio, Tanaka, Yasushi
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Blackwell Publishing Ltd 2018
Materias:	Brief Reports
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5947308/ https://www.ncbi.nlm.nih.gov/pubmed/29316197 http://dx.doi.org/10.1111/dom.13211

Ejemplares similares

Effects of a novel selective peroxisome proliferator‐activated receptor‐α modulator, pemafibrate, on hepatic and peripheral glucose uptake in patients with hypertriglyceridemia and insulin resistance
por: Matsuba, Ikuro, et al.
Publicado: (2018)

Liraglutide Reduces Visceral and Intrahepatic Fat Without Significant Loss of Muscle Mass in Obese Patients With Type 2 Diabetes: A Prospective Case Series
por: Ishii, Satoshi, et al.
Publicado: (2019)

Comparison of Combined Tofogliflozin and Glargine, Tofogliflozin Added to Insulin, and Insulin Dose-Increase Therapy in Uncontrolled Type 2 Diabetes
por: Suzuki, Katsunori, et al.
Publicado: (2016)

Factors Associated With Reduced Efficacy of Sitagliptin Therapy: Analysis of 93 Patients With Type 2 Diabetes Treated for 1.5 Years or Longer
por: Kanamori, Akira, et al.
Publicado: (2013)

Fasting Insulin Levels and Metabolic Risk Factors in Type 2 Diabetic Patients at the First Visit in Japan: A 10-year, nationwide, observational study (JDDM 28)
por: Matsuba, Ikuro, et al.
Publicado: (2012)

Differing Effect of the Sodium-Glucose Cotransporter 2 Inhibitor Ipragliflozin on the Decrease of Fat Mass vs. Lean Mass in Patients With or Without Metformin Therapy
por: Nagai, Yoshio, et al.
Publicado: (2019)

Ipragliflozin Improves Glycemic Control and Decreases Body Fat in Patients With Type 2 Diabetes Mellitus
por: Kawata, Takehiro, et al.
Publicado: (2017)

Influence of an SGLT2 inhibitor, tofogliflozin, on the resting heart rate in relation to adipose tissue insulin resistance
por: Nojima, T., et al.
Publicado: (2020)

Uric acid lowering in relation to HbA1c reductions with the SGLT2 inhibitor tofogliflozin
por: Ouchi, Motoshi, et al.
Publicado: (2018)

Secretory units of islets in transplantation index is a useful clinical marker to evaluate the efficacy of sitagliptin in treatment of type 2 diabetes mellitus
por: Kubota, Akira, et al.
Publicado: (2011)

Association of estimated plasma volume and weight loss after long‐term administration and subsequent discontinuation of the sodium‐glucose cotransporter‐2 inhibitor tofogliflozin
por: Matsubayashi, Yasuhiro, et al.
Publicado: (2021)

Multinational Observational Study to Understand Insulin Treatment Intensification: Japanese Subgroup Analysis of the MOSAIc Study
por: Matsuba, Ikuro, et al.
Publicado: (2022)

Tofogliflozin, a sodium/glucose cotransporter 2 inhibitor, attenuates body weight gain and fat accumulation in diabetic and obese animal models
por: Suzuki, M, et al.
Publicado: (2014)

Effect of Caloric Intake 25 or 30 kcal/kg/day on the Glycemic Control in Obese Patients With Type 2 Diabetes
por: Masuda, Kiyomi, et al.
Publicado: (2013)

Present status of insulin therapy for type 2 diabetes treated by general practitioners and diabetes specialists in Japan: Third report of a cross‐sectional survey of 15,652 patients
por: Arai, Keiko, et al.
Publicado: (2012)

Effect of the Dipeptidyl Peptidase-4 Inhibitor Sitagliptin on Muscle Mass and the Muscle/Fat Ratio in Patients With Type 2 Diabetes
por: Ishii, Satoshi, et al.
Publicado: (2020)

Ramadan Fasting Decreases Body Fat but Not Protein Mass
por: Fahrial Syam, Ari, et al.
Publicado: (2016)

Effect of Tofogliflozin on Body Composition and Glycemic Control in Japanese Subjects with Type 2 Diabetes Mellitus
por: Kamei, Shinji, et al.
Publicado: (2018)

A survey of clinical physician's perceptions of stigma and advocacy in patients with type 2 diabetes in Kanagawa, Japan
por: Matsuzawa, Yoko, et al.
Publicado: (2022)

Prognostic impact of chronological age on efficacy of immune checkpoint inhibitors in non‐small‐cell lung cancer: Real‐world data from 86 173 patients
por: Takamori, Shinkichi, et al.
Publicado: (2021)

Factor Analysis of Changes in Hemoglobin A1c After 12 Months of Sitagliptin Therapy in Patients With Type 2 Diabetes
por: Yuasa, Shouhei, et al.
Publicado: (2016)

Complementary and Alternative Approaches to Biomedicine
por: Matsuba, Shintaro
Publicado: (2004)

Combination of tofogliflozin and pioglitazone for NAFLD: Extension to the ToPiND randomized controlled trial
por: Yoneda, Masato, et al.
Publicado: (2022)

Effects of Tofogliflozin on Cardiac Function in Elderly Patients With Diabetes Mellitus
por: Higashikawa, Toshihiro, et al.
Publicado: (2020)

Association of increased hepatic insulin clearance and change in serum triglycerides or β‐hydroxybutyrate concentration via the sodium/glucose‐cotransporter 2 inhibitor tofogliflozin
por: Matsubayashi, Yasuhiro, et al.
Publicado: (2020)

Sodium–glucose cotransporter 2 inhibitor, tofogliflozin, shows better improvements of blood glucose and insulin secretion in patients with high insulin levels at baseline
por: Tobe, Kazuyuki, et al.
Publicado: (2017)

The Mechanism by Which Safflower Yellow Decreases Body Fat Mass and Improves Insulin Sensitivity in HFD-Induced Obese Mice
por: Zhu, Huijuan, et al.
Publicado: (2016)

A Study of Seasonal Variation in the Effect of Add-On Sitagliptin on Blood Glucose Control in Insulin-Treated Patients With Type 2 Diabetes
por: Takai, Masahiko, et al.
Publicado: (2020)

Correlation between liver fat content with dyslipidemia and Insulin resistance
por: Saran, Sanjay, et al.
Publicado: (2013)

Body Fat Distribution and Insulin Resistance
por: Patel, Pavankumar, et al.
Publicado: (2013)

Is there a distinct phenotype of diabetic patients who benefit from tofogliflozin?
por: Patoulias, Dimitrios Ioannis
Publicado: (2018)

Geographic patterns in patient demographics and insulin use in 18 countries, a global perspective from the multinational observational study assessing insulin use: understanding the challenges associated with progression of therapy (MOSAIc)
por: Polinski, Jennifer M., et al.
Publicado: (2015)

A Case of Hyperandrogenism, Insulin Resistance, and Acanthosis Nigricans Syndrome; Increase in Proliferating Cell Nuclear Antigen and Decrease in Loricrin in Acanthosis Nigricans
por: Saito, Kanami, et al.
Publicado: (2016)

Impact of the 8-week Administration of Tofogliflozin for Glycemic Control and Body Composition in Japanese Patients with Type 2 Diabetes Mellitus
por: Hirose, Sachie, et al.
Publicado: (2016)

Influence of long term administration of tofogliflozin on chronic inflammation of visceral adipose tissue in mice with obesity induced by a high-fat diet
por: Shirakawa, Kohsuke, et al.
Publicado: (2019)

Myostatin Inhibition in Muscle, but Not Adipose Tissue, Decreases Fat Mass and Improves Insulin Sensitivity
por: Guo, Tingqing, et al.
Publicado: (2009)

Is a Switch From Insulin Therapy to Liraglutide Possible in Japanese Type 2 Diabetes Mellitus Patients?
por: Kawata, Takehiro, et al.
Publicado: (2014)

Body Mass, Total Body Fat Percentage, and Visceral Fat Level Predict Insulin Resistance Better Than Waist Circumference and Body Mass Index in Healthy Young Male Adults in Indonesia
por: Kurniawan, Liong Boy, et al.
Publicado: (2018)

Salt overload in fructose-fed insulin-resistant rats decreases paraoxonase-1 activity
por: Dornas, Waleska Cláudia, et al.
Publicado: (2012)

Development of a simple prediction model for adrenal crisis diagnosis
por: Katabami, Takuyuki, et al.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_ko5n0h8rlvcrlfjpucuovlnmi2